TG Therapeutics is heading back to the drawing board after new data showed its cancer drug had an elevated risk of death, plucking Ukoniq off the market for the two indications it won accelerated a | TG Therapeutics is heading back to the drawing board after new data showed its cancer drug had an elevated risk of death, plucking Ukoniq off the market for the two indications it won accelerated approval for, in addition to withdrawing an approval request for a combo med.